Before revision: Commercial development In February 2019 the FDA issued a warning about companies offering young blood transfusions stating: Ambrosia A startup company, Ambrosia, has been selling "young blood transfusions" for 8,000 since 2016 framing it as a clinical trial, to see if such transfusions lead to changes in the blood of recipients.
After revision: Commercial development In February 2019 the FDA issued a warning about companies offering young blood transfusions stating: Ambrosia A startup company, Ambrosia, has been selling "young blood transfusions" for 8,000 since 2016 , as a clinical trial, to see if such transfusions lead to changes in the blood of recipients.